Agentic AI Poised too Transform Healthcare & Life Sciences, Says AWS Healthcareโค & โขResearch GM
Seoul, South Korea – Cho Min-sung, โGeneral Manager of Amazon Web Services (AWS) Healthcare & Research Division, highlighted the potentialโข of “agentic AI” to revolutionizeโ workflows in โขthe medical and life science sectors at the Future Healthcare Trend Conference hosted by Medigate News on November 2nd at COEX in Seoul.
Cho defined agentic โคAIโค as artificial โฃintelligence capable of โautonomous โreasoningโฃ and action towards a specific goal, moving beyond theโ limitations of traditional generative โAI. He presented its potential applications across patient care, clinical trials, andโ new drug development. Unlike generative AI which providesโ answers based onโค direct โฃprompts, agentic โฃAI proactively sets objectives,โข explores relevant knowledge, andโ assists medical professionals.
The adoptionโ of agentic AI is โคexpanding from processing patient medical records to supporting clinical trials and treatment optimization.Cho โnoted that medical institutions andโค pharmaceutical companiesโ internationally are already exploring its implementation in areas like general administrative tasks, streamliningโค hospital โbusiness processes – including reducing emergency room waitโข times โand predicting patient re-admission risk – and acceleratingโข new drug โคdiscovery thru biomarker identification.
He specifically pointed to oncology as a field where the application of agentic AI is beingโค most actively discussed, due to the specialized terminology and communication nuances within the discipline.
according to Gartner, currently only 1% of companies are actively implementing agentic AI, โbut a meaningful 33% plan to do so by 2028. AWSโฃ anticipatesโ that over 15% of commercial software will incorporate agentic AI, forecasting a 35-40% annual โgrowth rate for the agentic AI market in theโฃ field over the โnext five years.
AWS is providing a suite of โtechnologies to โfacilitateโค this transition, includingโข Amazon โฃBedrock Agent โขand Strand Agent, designed toโ support customerโฃ development of agentic โคAI solutions.โค The AWS Marketplace offers a subscription-based ecosystem ofโ solutions, alongside data explanation capabilities for trading pseudonymized and anonymized โdata. โ AWS reports having already reduced developer work hours by over 4,500 years and lowered internal costs by โฃmore than $2.6 billion annually โคthrough large-scale legacy โฃsystem conversions and application code migration utilizing these technologies.
Cho emphasized that the speed of adoption โคwill be โฃdirectly correlated to data availability, stating, โข”Agent AI will vary depending on how much dataโข I have, but it will vary โคdepending on howโ fast it โคstarts.”
To accelerate implementation, AWS โis actively supporting partnersโ in bringing innovative ideas to โfruition through experimental challenges. โคโ The company hasโฃ also launched medical andโข lifeโข science-specific open-source agent toolkits, enabling hospitals, pharmaceutical companies, and researchโ institutes to โขeasily deploy customized agents tailored to thier specific needs. The AWS โขLife Science Agent Toolkit currently features over 20 starter agents โฃcoveringโข areasโ like biomarker analysis,โ clinical statistical analysis,โข andโฃ medical video interpretation.
Cho Min-sung brings โa strong โขbackground in medical innovation, combining โcloud and AI expertise. He holds a master’s degree from Yonsei โฃUniversity and completed hisโข bachelor’s at the Korea Institute of Science โขand Technology (KAIST).Priorโ toโ AWS, โheโ worked โin medical IT at GE Healthcare. Currently,he is focused on leveraging generative AI to enhance efficiency โคin the medical fieldโ and improve data accessibility for researchers.